ArticlePediatric pulmonology2026
Urine Metabolomics to Predict Bronchopulmonary Dysplasia: A Single-Center Prospective Study.
Article in Pediatric pulmonology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bronchopulmonary dysplasia and prematurity-associated lung disease: emerging therapies to improve lifelong respiratory outcomes.European journal of pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundBronchopulmonary dysplasia (BPD) remains a major cause of morbidity in extremely preterm infants, yet early prediction remains limited using clinical factors alone. Urine is a non-invasive and routinely available specimen in the NICU, making it well suited for early biomarker discovery.
objectiveTo determine whether urinary metabolites collected on day of life five can predict BPD development in preterm neonates and to identify associated metabolic pathways. STUDY
designIn this prospective single-center study, urine samples collected on day of life five from preterm infants were analyzed using liquid chromatography-mass spectrometry-based metabolomics. A multivariable modeling approach integrating urinary metabolites with clinical features was used to identify metabolic patterns associated with subsequent BPD development. Model performance was assessed using area under the receiver operating characteristic curve (AUC).
resultsEarly urinary metabolomic profiling identified a multivariate metabolic signature associated with later BPD development (40.9% of infants; n = 44). The integrated clinical-metabolic model demonstrated good predictive performance (AUC = 0.805) using a limited number of metabolites and clinical variables. Key metabolic pathways implicated included purine metabolism, oxidative stress, and amino acid degradation, consistent with known mechanisms of lung injury in prematurity.
conclusionA single urine sample collected early in life can provide clinically meaningful information about BPD risk. These findings support the feasibility of urine-based, non-invasive metabolic profiling as a complement to existing clinical risk assessment tools. Larger, multicenter studies are needed to validate these findings and define their role in clinical care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.